Phase I Evaluation of Fenretinide (NSC 374551).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Fenretinide (Primary)
- Indications Sarcoma; Solid tumours
- Focus Adverse reactions
- 11 Apr 2014 Biomarkers information updated
- 18 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2010 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.